| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.15▼ | 1.15▼ | 1.14▲ | 1.11▲ | 1.15▼ |
| MA10 | 1.14▲ | 1.14▲ | 1.12▲ | 1.11▲ | 1.19▼ |
| MA20 | 1.14▲ | 1.12▲ | 1.10▲ | 1.21▼ | 1.11▲ |
| MA50 | 1.14▲ | 1.11▲ | 1.12▲ | 1.21▼ | 1.99▼ |
| MA100 | 1.12▲ | 1.11▲ | 1.15▼ | 1.13▲ | 3.01▼ |
| MA200 | 1.11▲ | 1.16▼ | 1.27▼ | 1.71▼ | 14.27▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.002▲ | 0.007▲ | -0.010▼ | 0.074▲ |
| RSI | 53.552▲ | 62.012▲ | 59.957▲ | 47.688▼ | 44.060▼ |
| STOCH | 50.000 | 68.855 | 74.545 | 39.515 | 38.204 |
| WILL %R | -25.000▲ | -26.667 | -26.667 | -57.627 | -58.459 |
| CCI | 37.917 | 86.667 | 91.270 | 5.360 | -36.938 |
|
Tuesday, July 08, 2025 05:00 AM
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company pioneering off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs).
|
|
Tuesday, July 08, 2025 04:34 AM
In an industry often defined by hype and regulatory hurdles, Adia Nutrition is quietly stacking real-world wins. With insurance-backed treatments, national exposure, and a scalable model already in ...
|
|
Saturday, July 05, 2025 12:33 AM
Trump said the U.S. will resume talks with China this week over a pending TikTok deal, saying that "we pretty much have a deal." ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/07/25 | 1.11 | 1.17 | 1.11 | 1.15 | 1,742,367 |
| 08/07/25 | 1.09 | 1.1153 | 1.085 | 1.09 | 756,042 |
| 07/07/25 | 1.09 | 1.13 | 1.05 | 1.06 | 1,299,600 |
| 03/07/25 | 1.12 | 1.155 | 1.11 | 1.12 | 1,213,797 |
| 02/07/25 | 1.18 | 1.22 | 1.10 | 1.12 | 2,663,479 |
| 01/07/25 | 1.14 | 1.20 | 1.10 | 1.14 | 1,510,014 |
| 30/06/25 | 1.07 | 1.20 | 1.05 | 1.12 | 1,978,107 |
| 27/06/25 | 1.09 | 1.095 | 1.025 | 1.04 | 3,748,222 |
| 26/06/25 | 1.16 | 1.1799 | 1.085 | 1.10 | 1,984,680 |
| 25/06/25 | 1.18 | 1.195 | 1.12 | 1.16 | 848,539 |
|
|
||||
|
|
||||
|
|